Professionals 201 Users Online

Botulinum Toxin Market

Booming demand for non-invasive cosmetic treatments to drive Botulinum Toxin market growth

Botulinum Toxin Market Segmented By Product - Type A and Type B Used in Cosmetic (Crow’s Feet, Forehead Lines, Frown Lines/Galbellar, Square Jaw/Masseter) and Therapeutic

Botulinum Toxins Market Outlook (2023-2033)

Worldwide revenue from the botulinum Toxin market stands at US$ 5.9 Bn in 2022, with the global market estimated to surge ahead at a CAGR of 7.1% to reach a valuation of US$ 12.6 Bn by the end of 2033.

Attributes Key Insights

Botulinum Toxin Market Size (2022)

US$ 5.9 Bn

Projected Market Value (2033)

US$ 12.6 Bn

Global Market Growth Rate (2023-2033)

7.1% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, Type A segment is expected to hold a largest market value of US$ 6.3 Bn by 2023. Overall, botulinum toxin market sales account for approximately 43.7% revenue share in the global medical aesthetics market, which was valued at around US$ 13.5 Bn at the end of 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of the Global Botulinum Toxin Market from 2013 to 2022 Vs Market Outlook for 2023 to 2033

The global market for botulinum toxin recorded a historic CAGR of 7.5% in the last 9 years from 2013 to 2022.

The average age of the population has increased due to increasing life expectancy. As the population ages, aesthetics and physical attractiveness become more important, which has a direct positive impact on the demand for Botox treatments, as a result the overall market is expected to flourish in the coming times.

Injections of Botox function by preventing the neurotransmitters from carrying pain signals to the brain. They have therefore been shown to be crucial in many people's efforts to cut down on migraine frequency and duration. The growth in occurrences of stress-triggered migraine and cluster headaches has had a significant favourable impact on the expansion of botulinum toxin injection operations, Botox treatment, and, subsequently, the botulinum toxin market.

Increased healthcare spending, which is a clear sign that more people are willing to undergo cosmetic surgeries. As a result, it indicates that numerous preventive treatments for wrinkles and glabellar lines that require for Botox procedures will rise. Other factors that support market expansion include rising demand for aesthetic procedures, an increase in non-surgical Botox treatments, regular approvals of medicines containing botulinum toxin, and advanced technologies such as dermal fillers and the usage of neuromodulators.

The global market is thus likely to show high growth over the coming years at a CAGR of 7.1% and reach a global market size of US$ 12.6 Bn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors Will Drive the Botulinum Toxin Market to Grow Over Forecast Period?

Increasing use of botulinum toxin in the APAC region

Among the few companies that operates in the botulinum toxin industry, three of them are based in Korea and supply the requirements of the region. Additionally, a variety of products are sold by unauthorized local market players, this scenario is a clear indication of the rising demand for botulinum toxin particularly in the APAC region. Established companies like Allergan have been forming strategic alliances to maintain the production and distribution of its botulinum toxin products in the Asia-Pacific area.

Better Efficacy of Botulinum Toxin with Combination Therapies”

Dermal filler and botulinum toxin are combined for more defined and long-lasting effects on procedures like reducing crow's feet and forehead wrinkles.

  • For instance, patients with hyperhidrosis who only respond partially to botulinum toxin may benefit more from a combined treatment that includes aluminium chloride hexahydrate antiperspirant than from only botulinum toxin alone.

In the same way, using botulinum toxin in conjunction with dermal fillers results in smoother appearance and long-lasting effects during cosmetic treatments.

Increasing frequency of approvals”

Numerous botulinum toxin products are frequently getting approved, which makes them more readily available and more reasonably priced for consumers to choose from. As a result, demand for all kinds of Botox procedures will increase globally. The non-invasive nature of therapeutic procedures utilising botulinum toxin makes them the most popular.

  • For instance, Allergan PLC announced in July 2020 that the FDA had approved its product BOTOX®, a supplemental Biologics License Application (sBLA) for the treatment of lower limb muscle spasticity in young patients older than 2 years old with cerebral palsy.
Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Is there Any Impact on the Growth of the Global Botulinum Toxin Market?

Challenging Counterfeit Products”

There are numerous counterfeit products on the market since botulinum toxin is made utilising microorganisms that are available to many parties. These products are easily accessible online and have no regulatory authority approval. Botulinum toxin counterfeit products are a serious problem, particularly in the Asia-Pacific region. The majority of the approved products have trouble gaining traction and surviving on the market.

“Substandard Reimbursement Coverage”

In general, there is no reimbursement for cosmetic procedures. Therefore, the patient is required for covering the full cost of the botulinum toxin cosmetic operation. Even if certain insurers might incorporate some of the reimbursement methods, they come at a very high premium. The Clostridium botulinum is the source of botulinum toxin. The majority of companies that produce botulinum toxin mainly produce the Type A. U.S. WorldMeds is the exclusive manufacturer of Type B. Additionally, companies in Asia are being sued on the grounds that the botulinum strain used to make botulinum toxin is a counterfeit.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Botulinum Toxin Market Booming?

“Growing Demand for Aesthetic Procedures”

The U.S. is expected to hold around 58.6% market share in the global botulinum toxin market at the end of 2023.

Botox procedures are in increasing demand due to the ageing population. Some of the key factors driving the market in the country include the rising number of non-surgical aesthetic procedures and the regular approval of various Botox medications. Over the course of the projection period, various advancements in the cosmetics industry and improved R&D efforts by major players will offer profitable prospects in the country.

Will the Germany Be a Lucrative Market for the Manufacturers?

“Better Outcomes at Affordable Prices”

With a 3.2% market share, Germany will hold a fair amount of share in global market at the end of 2023.

Dermal fillers and Botox procedures are very popular in Germany due to their low cost. Additionally, a lot of dermatology clinics, salons, and spas offer these procedures at reasonable costs with high success rates, which also contributes to the country's rising demand for botulinum toxin.

How is Japan Emerging as a Prominent Market for Botulinum Toxin?

“Prevalence of Hospital Acquired Infections (HAIs)”

Japan is estimated to hold market share of about 3.1% of the global botulinum toxin market in 2023.

The market is growing since more people in their 60s and older are living longer and are more susceptible to age-related diseases like acne, wrinkles, and scars. The demand for botulinum toxins has been rising rapidly in Japan because to the large patient base using facial dermal fillers and Botox. Furthermore, a significant demand for facial aesthetics is predicted to fuel market growth.

Category-wise Insights

Which Product is Driving Growth of the Global Market?

“High Usage of Type A Toxins”

Type A segment is expected to hold highest share of around 99.3% of the product segment by the end of 2023.

All cosmetic procedures that are in high demand globally use type A toxin. The world's working population is very active in cosmetic procedures. The increased demand for Botox operations worldwide is being fuelled by factors like as rising use of social media and adoption of the procedure as a preventive maintenance therapy.

Which Application is Expected to Dominate the Global Market?

“Therapeutic Applications of Botulinum Toxins”

Therapeutic segment is expected to be the dominating segment by the end of 2023 with majority of the market of about 60.0%.

Botulinum toxin is used therapeutically to treat a variety of conditions, such as hyperhidrosis, overactive bladders, chronic migraines, and muscle stiffness.

  • AbbVie's BOTOX® (onabotulinumtoxinA) was given U.S. FDA approval in 2004 for the treatment of severe primary axillary hyperhidrosis.

In addition to the US, at least 20 other nations have authorised the use of Botox to treat excessive sweating.

Which End User is Expected to Emerge as a Market Leader in the Future?

“Increasing Number of Hospitals with Better Infrastructure”

Specialty clinics segment is expected to hold the larger share of about 46.5% by the end of 2023.

Specialty clinics are preferred majorly by patients due to their advanced treatment services and presence of specialized professionals and advanced equipment.

Competition Landscape

Key players in the botulinum toxins use strategies to obtain approval from numerous regulatory bodies around the world and establish joint ventures to increase their market position.

Key instances include:

  • In April 2022, PatientFi, a start-up in the patient payments industry that lowers the cost of elective procedures, has expanded its co-marketing partnership with Allergan Aesthetics to give customers interested in procedures like Botox and other cosmetic treatments the option for financing.
  • In Aug 2021, the Russian Federal Service for Surveillance in Healthcare gave Merz Therapeutics approval for the use of Xeomin, a neurotoxin known as incobutlinumtoxinA, to treat chronic sialorrhea brought on by neurodevelopmental problems in children between the ages of 2 and 17 years old.

Botulinum Toxins Industry Report Scope

Attribute Details

Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Product
  • Application
  • End user
  • Region

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Key Companies’ Profile

  • Allergan PLC
  • Ipsen
  • Merz Pharma GmbH & Co. KGaA
  • Daewoong Pharmaceuticals
  • Medy-Tox
  • Hugel
  • U.S. WorldMeds
  • Hugh Source (International) Ltd.

Customization & Pricing

Available upon Request

Key Segments Covered in Botulinum Toxins Industry Research


  • Type A
  • Type B


  • Cosmetic
    • Crow’s Feet
    • Forehead Lines
    • Frown Lines/Galbellar
    • Square Jaw/Masseter
    • Others
  • Therapeutic
    • Chronic Migraine
    • Muscle Spasm
    • Over reactive Bladder
    • Hyperhidrosis
    • Others

End User:

  • Hospitals
  • Specialty Clinics
  • Spas & Beauty Clinics


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Allergan Plc
  • Daewoong Pharmaceuticals Co.Ltd.
  • HUGEL Pharma
  • Ipsen Group
  • Medy-Tox Inc
  • Merz Pharma GmbH & Co. KGaA
  • U.S. WorldMeds
  • Hugh Source (International) Ltd.

- Frequently Asked Questions -

The global market is currently valued at around US$ 5.9 Bn in 2022.

Sales of the market are set to witness growth at a CAGR of 7.1% and be valued at around US$ 12.6 Bn by 2033.

Demand for the market increased at a 7.5% CAGR from 2013 to 2022.

U.S., Italy, Germany, Japan and Canada accounted for the major share in the global market as of year 2022, holding around 74.1% market share.

The U.S. is expected to hold around 58.6% market share in the global botulinum toxins market at the end of 2023.

Latin America will account for around 4.2% share of the global market in 2023.

Japan is estimated to hold market share of about 3.1% of the global botulinum toxins market in 2023.

With a 3.2% market share, Germany will hold a fair amount of share in global market at the end of 2023.

UK market is set to expand at a CAGR growth rate of close to 6.2% over the forecast period.

Indian market is set to expand at a CAGR growth rate of close to 8.1% over the forecast period.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate